이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Protagonist Therapeutics 대차 대조표 상태
재무 상태 기준 확인 6/6
Protagonist Therapeutics 의 총 주주 지분은 $560.4M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $629.3M 및 $68.8M 입니다. Protagonist Therapeutics 의 EBIT는 $148.7M 이며 이자보상배율은 -8.9 입니다. $322.6M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
0%
부채 비율
US$0
부채
| 이자 보상 비율 | -8.9x |
| 현금 | US$322.64m |
| 주식 | US$560.44m |
| 총 부채 | US$68.83m |
| 총 자산 | US$629.28m |
최근 재무 상태 업데이트
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09재무 상태 분석
단기부채: PTGX 의 단기 자산 ( $627.6M )이 단기 부채( $39.9M ).
장기 부채: PTGX 의 단기 자산( $627.6M )이 장기 부채( $28.9M ).
부채 대 자본 내역 및 분석
부채 수준: PTGX 부채가 없습니다.
부채 감소: PTGX 5년 전에 부채가 없었습니다.
부채 범위: PTGX 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: PTGX 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.